Bioinvent International AB, of Lund, Sweden, said it has signed a manufacturing agreement with an undisclosed U.S. cell therapy company for the production of cGMP-compliant material to support its clinical development programs. The manufacturing agreement is expected to generate revenue of approximately $1.5 million, mainly in 2019. No other terms of the deal were released.